A novel gel formulation of 0.25% tretinoin and 1.2% clindamycin phosphate: Efficacy in acne vulgaris patients aged 12 to 18 years

Pediatric Dermatology

Volumn 26, Issue 3, 2009, Pages 257-261

  Eichenfield, Lawrence F ^a,b   Wortzman, Mitchell ^c  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c The Dermatology Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN PHOSPHATE; PLACEBO; RETINOIC ACID;

ACNE VULGARIS; ADOLESCENT; ADULT; APPLICATION SITE REACTION; ARTICLE; BEDTIME DOSAGE; CHILD; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SKIN INFLAMMATION; TREATMENT DURATION;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CLINDAMYCIN; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRETINOIN;

EID: 67650491401     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2008.00862.x     Document Type: Article

References (12)

1. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003 49 (Suppl S1 S37.
2. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003 49 (Suppl S200 210.
3. Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Therapy Lett 2004 9 : 1 3.
4. Goodman G. Acne and acne scarring - the case for active and early intervention. Aust Fam Physician 2006 35 : 503 504.
5. Schlessinger J, Menter A, Gold M et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007 6 : 607 615.
6. Wolf JE Jr., Kaplan D, Kraus SJ et al. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003 49 (Suppl S211 217.
7. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006 54 : 73 81. (Pubitemid 41832461)
8. Leyden J, Wortzman M. A novel gel formulation of clindamycin phosphate/tretinoin is not associated with acne flaring. Cutis 2008 82 : 151 156.
9. Kircik L, Peredo M, Bucko A et al. Safety of a novel gel formulation of tretinoin 0.025% and clindamycin phosphate 1.2%: results from a 52-week open-label study. Cutis 2008 82 : 358 366.
10. Plott RT. Unique aqueous gel formulation results in reduced risk of tretinoin-induced irritation bioassay. J Am Acad Dermatol 2007 26 (Suppl. 2 AB21.
11. Del Rosso JQ. Updates & perspectives on management of common dermatologic disorders. J Drugs Dermatol 2007 6 : 662 664.
12. ®. http://www.medicis.com/products/pi/pi-ziana.pdf. Accessed on November 28, 2007.